Clinical Trials Browser

Phase 2 × NETWORK × Amifostine × Clear all

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases

NCT00003811 2013-07-04

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Phase 2 Completed

27 enrolled

GenitourinaryGynecologic

Ovarian Germ Cell Cancer, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00003624 2013-04-11

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Phase 2 Terminated

GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Neurotoxicity Syndromes

NCT00025298 2012-09-24

Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

Phase 2 Terminated

5 enrolled

Head & Neck

Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Radiation Injuries, Drug-Related Side Effects and Adverse Reactions

NCT00003127 2012-06-14

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer

Phase 2 Completed

57 enrolled

Gynecologic

Endometrial Neoplasms

Clinical Trials

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer